seminar on chiral columns April 4
Rekha D. Shah, Ph.D.
Johnson & Johnson Pharmaceutical Research & Development
Spring House, PA
Monday, April 4, 2005
Disque Hall (Building 12), Room 919
3141 Chestnut Street, Philadelphia, PA 19104
3:30 PM Refreshments
3:40 PM Seminar - "Chiral Columns or Chiral Detectors? : A Question of Importance in HPLC Chiral Methods Development"
Abstract
Chiral molecules, especially chiral drug molecules pose challenges both from a synthetic as well as an analytical perspective. When a new molecular entity, which is chiral, is identified, the challenge for the process chemists is to decide how to prepare it on a large scale. Two possible ways to prepare an enantiomerically pure drug substance are by asymmetric synthesis or by resolution (classical or chromatographic). In any event it is essential to develop an enantiomeric purity method(s) to determine the %enantiomeric purity (%ee) of the product as well as for the starting material and the intermediate(s).
Developing an enantiomeric purity method is less complicated in the case where a pure racemate is available and the compound is soluble in the mobile phase. But when the racemate is not chemically pure, then the impurity peak(s) can lead to incorrect interpretations, and developing a method becomes problematic. In such situations, chiroptical detectors can be valuable since they give a response to only chiral molecules. In this presentation we will discuss chiral method development techniques using chiral columns and chiral detectors as well as the applications of chiroptical detectors in the determination of %ee without separating enantiomers.
Johnson & Johnson Pharmaceutical Research & Development
Spring House, PA
Monday, April 4, 2005
Disque Hall (Building 12), Room 919
3141 Chestnut Street, Philadelphia, PA 19104
3:30 PM Refreshments
3:40 PM Seminar - "Chiral Columns or Chiral Detectors? : A Question of Importance in HPLC Chiral Methods Development"
Abstract
Chiral molecules, especially chiral drug molecules pose challenges both from a synthetic as well as an analytical perspective. When a new molecular entity, which is chiral, is identified, the challenge for the process chemists is to decide how to prepare it on a large scale. Two possible ways to prepare an enantiomerically pure drug substance are by asymmetric synthesis or by resolution (classical or chromatographic). In any event it is essential to develop an enantiomeric purity method(s) to determine the %enantiomeric purity (%ee) of the product as well as for the starting material and the intermediate(s).
Developing an enantiomeric purity method is less complicated in the case where a pure racemate is available and the compound is soluble in the mobile phase. But when the racemate is not chemically pure, then the impurity peak(s) can lead to incorrect interpretations, and developing a method becomes problematic. In such situations, chiroptical detectors can be valuable since they give a response to only chiral molecules. In this presentation we will discuss chiral method development techniques using chiral columns and chiral detectors as well as the applications of chiroptical detectors in the determination of %ee without separating enantiomers.
posted by Jean-Claude Bradley at 3:51 PM
0 comments
